甘丙肽及其受体在中枢神经系统疾病中的作用

中枢神经系统疾病因其发病机制复杂而难以找到药物作用的有效靶点。甘丙肽(galanin, GAL)因其广泛的中枢神经系统分布并与多种神经系统疾病密切相关而进入人们的视线。现已证明,GAL与三种G蛋白偶联受体(GALR1-3)结合后,通过抑制cAMP/PKA(GALR1、GALR3)和激活磷脂酶C(GALR2)等信号通路调节众多生理和病理过程。本文概述了近年来GAL及其受体在中枢神经系统疾病中的作用的研究进展,旨在为理解这些疾病的发病机制以及靶向药物的研发提供新的指导。     

甘丙肽2型受体在HEK293A细胞中的同源二聚化研究

G蛋白偶联受体二聚化在受体的转运和信号转导中起着重要的调节作用.为了验证甘丙肽2型受体(GalR2)是否形成同源二聚体,本实验分别构建了N端带FLAG和HA标签的GalR2融合蛋白,并转染到HEK293A细胞中.Western blot发现,除了相当于GalR2分子量的位置有条带之外,在大约2倍于GalR2分子量的位置...     

甘丙肽研究进展

甘丙肽存在于外周和中枢神经系统。它以其广泛的抑制功能参与调节胃肠、泌尿生殖系统平滑肌收缩,胰岛素、垂体激素的分泌而实现它作为神经调制物在外周和中枢的作用。它协同吗啡镇痛、抑制记忆过程的作用将具有很高的临床研究意义。     

甘丙肽对抑郁症状的调控作用及其机制的研究进展

甘丙肽(galanin, GAL)作为治疗抑郁症的可能靶点被关注已久,但目前仍未有广泛应用的GAL类抗抑郁药物。GAL可与3种G蛋白偶联受体(GalR1~3)结合,GalR1和GalR3介导促进抑郁的作用,GalR2介导抗抑郁的作用。GAL的N端有生物活性的片段GAL (1-15),通过其受体GalR1-GalR2异聚体(heteromer),介导比GAL更强的调节抑郁效应。GAL (1-15)还可以通过GalR1-GalR2异聚体与5-羟色胺1A受体(5-HT1AR)相互作用形成GalR1-GalR2-5-HT1AR异聚体的方式,加强5-HT1AR激动剂的抗抑郁效果。此外,GAL及其受体还与去甲肾上腺素、神经肽Y、脑源性神经营养因子、多巴胺等递质或因子交互作用调节抑郁。本文梳理GAL及其受体对抑郁的调节作用及其可能机制,并对以GAL及其受体为靶点开发的药物应用于临床治疗抑郁症的可能性进行探讨。     

甘丙肽对PC12细胞和B104细胞增殖的不同影响

本实验运用PCI2细胞和B104细胞对甘丙肽（GAL）在神经增殖上的作用进行了研究。运用RT-PCR方法检测GAL及其受体在PCI2细胞和B104细胞中的表达：运用MTT法检测GAL及其受体激动剂、拮抗剂对两种细胞增殖的影响。结果显示：PCI2细胞表达所有三种GAL受体（GalRs）．而不表达GAL;B104细胞表达GAL及两种受体GaIR2和GalR3,而不表达GalRl;GAL及其受体激动剂GAL1-11和GAL2-11能够明显地抑制PC12细胞增殖、却会明显促进B104细胞的增殖。这些效应皆可被非特异性GAL受体拮抗剂M35所阻断。结果说明,GAL可以通过其受体影响细胞的增殖．并且不同受体可能介导不同的作用。     

综述与专论：甘丙肽对抑郁症状的调控作用及其机制的研究进展

甘丙肽(galanin, GAL)作为治疗抑郁症的可能靶点被关注已久,但目前仍未有广泛应用的GAL类抗抑郁药物。GAL可与3种G蛋白偶联受体(GalR1～3)结合,GalR1和GalR3介导促进抑郁的作用,GalR2介导抗抑郁的作用。GAL的N端有生物活性的片段GAL (1-15),通过其受体GalR1-GalR2异聚体(heteromer),介导比GAL更强的调节抑郁效应。GAL (1-15)还可以通过GalR1-GalR2异聚体与5-羟色胺1A受体(5-HT1AR)相互作用形成GalR1-GalR2-5-HT1AR异聚体的方式,加强5-HT1AR激动剂的抗抑郁效果。此外,GAL及其受体还与去甲肾上腺素、神经肽Y、脑源性神经营养因子、多巴胺等递质或因子交互作用调节抑郁。本文梳理GAL及其受体对抑郁的调节作用及其可能机制,并对以GAL及其受体为靶点开发的药物应用于临床治疗抑郁症的可能性进行探讨。     

靶向G蛋白偶联受体的肽类药物

G蛋白偶联受体(G protein-coupled receptors,GPCRs)是哺乳动物体内最大的细胞膜表面受体家族,具有7次跨膜螺旋结构.人类基因组编码约800种不同类型的GPCRs,广泛参与了代谢性疾病及肿瘤等多种重大疾病的病理过程,使之成为药物研发的热门靶点.肽是介于氨基酸和蛋白质之间的一类物质,由两个至几...     

胰岛素原C肽作用机制

Ｃ肽是胰岛素原中连接ＡＢ两条链的连接肽。在胰岛 β细胞分泌颗粒中 ,胰岛素原经蛋白酶裂解 ,形成等摩尔由ＡＢ链组成的胰岛素和Ｃ肽 ,然后分泌并进入血液。Ｃ肽的种族差异很大 ,其中人Ｃ肽含 31个氨基酸。在胰岛素原分子中Ｃ肽对胰岛素原分子的折叠、二硫键的正确配对等分子结构的形成起重要作用 ,而血液中游离Ｃ肽的生理功能却一直不清楚。近来的研究发现 ,给予Ｉ型糖尿病大鼠超生理剂量的人Ｃ肽配伍胰岛素治疗 ,能防止血管、神经机能障碍[1] ,长期 (3个月 )给予胰岛素配伍Ｃ肽 ,可使Ｉ型糖尿病病人减少尿白蛋白排泄率 ,改善肾功能和自主…     

鲜味受体研究进展

味觉对于生命具有重要作用,在一定程度上确定了人类对事物的选择。味觉由甜、咸、苦、酸和鲜等5种基本味道组成,味觉的感知是通过存在于舌上味觉表面的特异性受体来实现的,大多数味觉受体都属于G蛋白偶联受体家族。近几年的研究揭示了感知鲜味的2类这样的受体,鲜觉受体的阐明使人们对味觉的理解有了较为全面的认识。     

神经多肽中的新成员：甘丙肽

甘丙肽(galanin,GAL)是由29个氨基酸残基组成的神经多肽,具有由123个氨基酸组成的前体蛋白,即前GAL原(prepro GAL)。甘丙肽样免疫反应物质(GAL-like immunoreactivity,GAL-LI)存在于脑和脊髓、周围神经系统和某些器官。在体内某些含有GAL-LI的细胞也存在儿茶酚胺、5-HT、GABA、乙酰胆碱等递质与神经多肽。新生鼠用辣椒素处理后,可减少脑内某些区域和脊髓内的GAL-LI的含量。GAL可减少血浆胰岛素的含量,增加血糖以及抑制肠道的运动。在大鼠第三脑室、人的静脉注射GAL,均可视察到血浆生长素含量增加。在大鼠下丘脑的室旁核内注射GAL可增强摄食活动。     

中枢ACTH受体研究进展

除垂体以外,中枢神经系统也含有促肾上腺皮质激素（ＡＣＴＨ）能神经元,其神经纤维在中枢具有较广泛的投射。ＡＣＴＨ相关肽类在中枢发挥着多种生理功能。近年来对于中枢ＡＣＴＨ受体的研究取得很大的进展,现已确认ＡＣＴＨ结合位点在中枢具有广泛的分布。新近克隆出的四种ＡＣＴＨ受体中,有两种是中枢神经系统占优势的受体亚型。     

Presence of an Endogenous Factor in Avian CNS with Agonistic Action on Benzodiazepine Receptors

In the present paper we describe the presence in avian CNS of an endogenous inhibitor of [³H]flunitrazepam binding. This compound was extracted from a synaptic membrane fraction isolated from chick optic lobe and brain using an exhaustive aqueous washing procedure, then purified by means of solid-phase extraction with C₁₈ cartridges and several HPLC steps until an homogeneous peak was obtained. Its chemical structure was studied by size-exclusion chromatography of the purified material which indicated that it possesses a molecular weight below 1350. Although its inhibitory activity was lost by HCl treatment, its peptidic nature was ruled out by an amino acid and N-terminal sequence analyses. Ultraviolet absorption spectrum showed two main peaks at 230 and 280 nm. The endogenous compound was found to inhibit competitively [³H]flunitrazepam binding to its recognition site without affecting [³H]GABA binding to the same receptor complex. The behavior of the endogenous factor in an in vitro GABA shift test and GABA-dependent chloride flux experiments were similar to that of benzodiazepine receptor agonists. In conclusion, these results demonstrate the existence in avian CNS of a competitive endogenous inhibitor of benzodiazepine binding with agonistic action on benzodiazepine receptors.     

G蛋白偶联受体及其类型的预测

G蛋白偶联受体是非常重要的信号分子受体,其功能失调会导致许多疾病的产生。在前期工作的基础上,作者将序列特征分析与支持向量机技术结合起来,通过分析序列的特征差异,对G蛋白偶联受体分子及其类型进行识别。首次提取了G蛋白偶联受体对应的mRNA序列的绝对密码子使用频率作为特征,这主要因为它既包含了基因密码子使用偏性的信息,也包含了基因所编码蛋白的氨基酸组成信息。结果显示：在G蛋白偶联受体序列及其类型预测的问题中,设计支持向量机分类器时,最好选择使用包含基因序列绝对密码子使用频率和蛋白序列双联氨基酸使用频率两部分信息的组合特征作为特征,同时采用径向基核作为核函数。     

Identification,biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate

The last two decades have provided a large weight of preclinical data implicating the neurokinin-1 receptor (NK₁) and its cognate ligand substance P (SP) in a broad range of both central and peripheral disease conditions. However, to date, only the NK₁ receptor antagonist aprepitant has been approved as a therapeutic and this is to prevent chemotherapy-induced nausea & vomiting (CINV). The belief remained that the full therapeutic potential of NK₁ receptor antagonists had yet to be realized; therefore clinical evidence that NK₁ receptor antagonists may be effective in major depression disorder, resulted in a significant further investment in discovering novel CNS penetrant druggable NK₁ receptor antagonists to address this condition. At GlaxoSmithKline after the discovery of casopitant, that went on to demonstrate efficacy as a novel antidepressant in the clinic, additional novel analogues of this NK₁ receptor antagonist were designed to further enhance its drug developability characteristics. Herein, we therefore describe the discovery process and the vivo pharmacological and pharmacokinetic profile of the new NK₁ receptor antagonist 3a (also called orvepitant), selected as clinical candidate and further progressed into clinical studies for major depressive disorder. Moreover, molecular modeling studies enabled us to improve the pharmacophore model of the NK₁ receptor antagonists with the identification of a region able to accommodate a variety of heterocycle moieties.     

Molecular characterization of the ligand binding site of the human galanin receptor type 2, identifying subtype selective interactions

To define the specific role of the galanin receptors when mediating the effect of galanin, effective tools for distinct activation and inhibition of the different receptor subtypes are required. Several of the physiological effects modulated by galanin are implicated to be mediated via the GalR2 subtype and have been distinguished from GalR1 effects by utilizing the Gal(2–11) peptide, recognizing only GalR2 and GalR3. In this study, we have performed a mutagenesis approach on the GalR2 subtype and present, for the first time, a molecular characterization of the interactions responsible for ligand binding and receptor activation at this receptor subtype. Our results identify four residues, His²⁵² and His²⁵³ located in transmembrane domain 6 and Phe²⁶⁴ and Tyr²⁷¹ in the extracellular loop 3, to be of great significance. We show evidence for the N-terminal tail of GalR2 to participate in ligand binding and that selective binding of Gal(2–11) includes interaction with the Ile²⁵⁶ residue, located at the very top of TM 6. In conclusion, we present a mutagenesis study on GalR2 and confer interactions responsible for ligand binding and receptor activation as well as selective recognition of the Gal(2–11) peptide at this receptor subtype. The presented observations could be of major importance for the design and development of new and improved peptide and non-peptide ligands, selectively activating the GalR2 subtype.     

Galanin Signaling in the Brain Regulates Color Pattern Formation in Zebrafish

1. Download : Download high-res image (251KB)
2. Download : Download full-size image

     

神经干细胞移植研究进展

神经干细胞是指一类具有自我更新能力和多向分化潜能的细胞,能分化成为神经元、星形胶质细胞、少突胶质细胞等众多神经细胞。成年哺乳动物内源性神经再生能力有限,无法弥补因神经疾病而导致的神经细胞缺失,因而,人们开始寻求外源性神经干细胞移植治疗中枢神经系统疾病的可能,在动物模型上开展了大量研究,并建立了多种移植方法。该文就神经干细胞的特性、来源、移植方式、在中枢神经系统疾病中的实验研究进展等作一综述。